Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable/Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Study completedNCT02073123
What this trial is testing

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Who this might be right for
Metastatic MelanomaStage III MelanomaStage IV Melanoma
NewLink Genetics Corporation 131
Large-scale testing (Phase 3)Study completedNCT03329846
What this trial is testing

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Who this might be right for
MelanomaSkin Cancer
Bristol-Myers Squibb 20
Testing effectiveness (Phase 2)Study completedNCT02158520
What this trial is testing

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Who this might be right for
Metastatic MelanomaMucosal MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7+2 more
Academic and Community Cancer Research United 24
Not applicableStudy completedNCT03504696
What this trial is testing

Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 400
Testing effectiveness (Phase 2)Looking for participantsNCT06797297
What this trial is testing

Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Who this might be right for
Melanoma
Innovent Biologics (Suzhou) Co. Ltd. 180
Early research (Phase 1)Study completedNCT03236935
What this trial is testing

Phase Ib of L-NMMA and Pembrolizumab

Who this might be right for
Non-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell Carcinoma+3 more
The Methodist Hospital Research Institute 12
Testing effectiveness (Phase 2)Study completedNCT00715793
What this trial is testing

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hussein Tawbi 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT05620134
What this trial is testing

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
CancerTumor, SolidAdvanced Solid Tumor+19 more
Salubris Biotherapeutics Inc 263
Early research (Phase 1)Study completedNCT01738139
What this trial is testing

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmC-KIT Tyrosine Kinase Protein OverexpressionClinical Stage IV Cutaneous Melanoma AJCC v8+6 more
M.D. Anderson Cancer Center 68
Testing effectiveness (Phase 2)Study completedNCT01009775
What this trial is testing

YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Who this might be right for
Melanoma
Astellas Pharma Inc 64
Large-scale testing (Phase 3)Looking for participantsNCT06246916
What this trial is testing

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Who this might be right for
Melanoma
Regeneron Pharmaceuticals 560
Early research (Phase 1)Ended earlyNCT01826448
What this trial is testing

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Who this might be right for
V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Daiichi Sankyo 13
Testing effectiveness (Phase 2)WithdrawnNCT04703426
What this trial is testing

Sargramostim (GM-CSF) + PD-1

Who this might be right for
Unresectable MelanomaMetastatic MelanomaStage III Melanoma+1 more
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT06265025
What this trial is testing

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Who this might be right for
Head and Neck CancerMalignant MelanomaColorectal Cancer+3 more
GeneMedicine Co., Ltd. 125
Not applicableStudy completedNCT01715077
What this trial is testing

Study of Ipilimumab in the Immune System

Who this might be right for
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
University Health Network, Toronto 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT03149029
What this trial is testing

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Who this might be right for
Metastatic Melanoma
Massachusetts General Hospital 16
Testing effectiveness (Phase 2)UnknownNCT01565837
What this trial is testing

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

Who this might be right for
Melanoma
Wolfram Samlowski 50
Testing effectiveness (Phase 2)Looking for participantsNCT05428007
What this trial is testing

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
MelanomaUnresectable Melanoma
NYU Langone Health 105
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Next Page